Dr. Dana Salzberg
Claim this profilePhoenix Childrens Hospital
Expert in Leukemia
Studies Acute Lymphoblastic Leukemia
13 reported clinical trials
38 drugs studied
Area of expertise
1Leukemia
Global LeaderPhiladelphia chromosome positive
BCR-ABL1 fusion positive
ABL-class fusion positive
2Acute Lymphoblastic Leukemia
Philadelphia chromosome positive
BCR-ABL1 fusion positive
ABL-class fusion positive
Affiliated Hospitals
Clinical Trials Dana Salzberg is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Non-TBI Conditioning
for HCT in Acute Lymphoblastic Leukemia
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regimen as part of the treatment cohort of the study. Subjects who are pre-HCT NGS-MRD positive will be treated as per treating center standard and will be followed in an observational cohort (HCT center standard of care).
Recruiting1 award Phase 2
More about Dana Salzberg
Clinical Trial Related5 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Dana Salzberg has experience with
- Daunorubicin Hydrochloride
- Cytarabine
- Thioguanine
- Methotrexate
- Pegaspargase
- Dexamethasone
Breakdown of trials Dana Salzberg has run
Leukemia
Acute Lymphoblastic Leukemia
Lymphoma
Klinefelter Syndrome and Triple X Syndrome.
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dana Salzberg specialize in?
Dana Salzberg focuses on Leukemia and Acute Lymphoblastic Leukemia. In particular, much of their work with Leukemia has involved Philadelphia chromosome positive patients, or patients who are BCR-ABL1 fusion positive.
Is Dana Salzberg currently recruiting for clinical trials?
Yes, Dana Salzberg is currently recruiting for 6 clinical trials in Phoenix Arizona. If you're interested in participating, you should apply.
Are there any treatments that Dana Salzberg has studied deeply?
Yes, Dana Salzberg has studied treatments such as Daunorubicin Hydrochloride, Cytarabine, Thioguanine.
What is the best way to schedule an appointment with Dana Salzberg?
Apply for one of the trials that Dana Salzberg is conducting.
What is the office address of Dana Salzberg?
The office of Dana Salzberg is located at: Phoenix Childrens Hospital, Phoenix, Arizona 85016 United States. This is the address for their practice at the Phoenix Childrens Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.